This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

8 Things That Could Lift Biotech Stocks Out of Bear Market

Biotech stocks are buried in a deep hole. To climb out, companies will have to generate some positive news.

Biotech Stock Mailbag: Snow Stops Sarepta's FDA Show, so What's Next?

TheStreet's Adam Feuerstein responds to reader questions about Sarepta and its Duchenne muscular dystrophy drug eteplirsen.

Alkermes Depression Drug Failure Crimps Future Growth Outlook

Alkermes said Thursday the experimental drug ALKS 5461 failed to improve depressive symptoms in patients with hard-to-treat depression, based on negative results from two late-stage clinical trials.

Acorda Acquires Parkinson's Drug Through Biotie Buyout

Acorda's all-cash tender offer values Biotie at $363 million, or $25.60 per ADS, representing a 96% premium over the stock's closing price on Friday.

Sarepta Plunges on Harsh FDA Eteplirsen Review Ahead of Next Week's Advisory Panel Meeting

The FDA's review team appears to cast significant doubt on eteplirsen's approval chances.

Investor Apathy Keeps Biotech Stocks in the Red

Nothing at the J.P. Morgan Healthcare Conference is convincing health care investors to step up and buy biotech stocks.

A Lack of News and Buzz at 'JPM16' Sinks Biotech Stocks

Biotech stocks large and small were plummeting as 2016's painful start began to turn torturous.

Brainstorm Recycles ALS Stem Cell Data to Boost Sagging Stock

A much-hyped press conference reveals nothing new about Brainstorm's stem-cell therapy for ALS.

Vertex Takes a Pass on 2016 Orkambi Cystic Fibrosis Sales Guidance

Vertex presents to investors on Monday at the J.P. Morgan Healthcare Conference.

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

I'm only making one big prediction this year: The five-year party which saw biotech stocks outperform the broader markets comes to an end in 2016.

Page 2 of 350
Top Rated Stocks Top Rated Funds Top Rated ETFs